Company: BLNE
Filing Date: 2025-03-27
Form Type: 424B7
Source: 0001641172-25-000822
Chunk: 15

Company: Beeline Holdings, Inc.
Filing Date: 2025-03-27
Form: 424B7
Chunk 15
---
 to C/M under the Purchase Agreement in ways with which you do not agree and in ways that may impair the value of your investment.

We currently intend to use the net proceeds from our sales of shares under the Purchase Agreement for working capital and general corporate purposes and may use such proceeds for other uses such as repayment of indebtedness, strategic transactions and/or initiatives. Our management has broad discretion as to the use of these proceeds and you will be relying on the judgment of our management regarding the application of these proceeds. We might apply these proceeds in ways with which you do not agree, or in ways that do not yield a favorable return. If our management applies these proceeds in a manner that does not yield a significant return, if any, on our investment of these net proceeds, it could compromise our ability to pursue our growth strategy and adversely affect the market price of our common stock.

Investors who buy shares at different times will likely pay different prices.

Pursuant to the Purchase Agreement, we will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to C/M. If and when we do elect to sell shares of our Common Stock to C/M pursuant to the Purchase Agreement, after C/M has acquired such shares, C/M may resell all, some or none of such shares at any time or from time to time in its discretion and at different prices. As a result, investors who purchase shares from C/M at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from C/M as a result of future sales made by us to C/M at prices lower than the prices such investors paid for their shares in this offering.

| S-18 |

<div align='center'>USE OF PROCEEDS</div>

This prospectus supplements relates to shares of our common stock that may be offered and sold from time to time by C/M. We will receive no proceeds from the sale of shares of common stock by C/M in this offering. However, we may receive gross proceeds estimated to be $3,500,000 (but may be less or more) under the Purchase Agreement as it relates to the common stock being offered pursuant to this prospectus supplement (not including the additional up to $4,000,000 for which we filed prior prospectus supplements on March 10, 2025 and March